anmelden
SPI
20.166,93
PKT
-159,86
PKT
-0,79
%
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
Analysen zu SPI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 11.09.17 | Swiss Re buy | Goldman Sachs Group Inc. | |
| 11.09.17 | Roche Conviction Buy | Goldman Sachs Group Inc. | |
| 08.09.17 | UBS buy | Citigroup Corp. | |
| 08.09.17 | Swiss Re buy | Deutsche Bank AG | |
| 08.09.17 | Zurich Insurance Hold | Deutsche Bank AG | |
| 08.09.17 | Zurich Insurance buy | Citigroup Corp. | |
| 07.09.17 | ABB (Asea Brown Boveri) Sell | Citigroup Corp. | |
| 07.09.17 | Swiss Re overweight | JP Morgan Chase & Co. | |
| 07.09.17 | Nestlé overweight | JP Morgan Chase & Co. | |
| 07.09.17 | ABB (Asea Brown Boveri) Neutral | JP Morgan Chase & Co. | |
| 07.09.17 | Holcim Neutral | JP Morgan Chase & Co. | |
| 07.09.17 | Novartis buy | HSBC | |
| 07.09.17 | Holcim Underweight | Barclays Capital | |
| 07.09.17 | Nestlé buy | Goldman Sachs Group Inc. | |
| 06.09.17 | Nestlé Neutral | BNP PARIBAS | |
| 06.09.17 | UBS buy | UBS AG | |
| 06.09.17 | Richemont Equal weight | Barclays Capital | |
| 05.09.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 05.09.17 | UBS buy | UBS AG | |
| 05.09.17 | Roche Neutral | UBS AG | |
| 05.09.17 | Givaudan market-perform | Bernstein Research | |
| 04.09.17 | UBS buy | UBS AG | |
| 04.09.17 | Givaudan Hold | Société Générale Group S.A. (SG) | |
| 04.09.17 | Zurich Insurance buy | HSBC | |
| 04.09.17 | Swiss Re Outperform | RBC Capital Markets | |
| 01.09.17 | Givaudan overweight | JP Morgan Chase & Co. | |
| 01.09.17 | Zurich Insurance Reduce | Commerzbank AG | |
| 31.08.17 | Givaudan Neutral | UBS AG | |
| 31.08.17 | Givaudan Hold | Kepler Cheuvreux | |
| 31.08.17 | Swiss Re Hold | Jefferies & Company Inc. | |
| 31.08.17 | UBS Neutral | BNP PARIBAS | |
| 31.08.17 | UBS Outperform | BNP PARIBAS | |
| 30.08.17 | Zurich Insurance Neutral | JP Morgan Chase & Co. | |
| 30.08.17 | Swiss Re Equal weight | Barclays Capital | |
| 29.08.17 | Novartis Neutral | JP Morgan Chase & Co. | |
| 29.08.17 | Swiss Re buy | Deutsche Bank AG | |
| 28.08.17 | Swiss Re buy | Deutsche Bank AG | |
| 28.08.17 | Novartis Neutral | UBS AG | |
| 28.08.17 | Novartis buy | Kepler Cheuvreux | |
| 28.08.17 | Swiss Re Underperform | BNP PARIBAS |